<DOC>
	<DOCNO>NCT00409357</DOCNO>
	<brief_summary>The primary objective ass dose-response relationship SL77.0499 10 ( alfuzosin hydrochloride ) 5 mg , 10 mg , 15 mg , placebo daily 12-week oral administration period efficacy patient low urinary tract symptom ( LUTS ) relate BPH . Secondary objective assess efficacy dose alfuzosin compare placebo ass safety dose alfuzosin .</brief_summary>
	<brief_title>Dose Ranging Study Alfuzosin Patients With Lower Urinary Tract Symptoms Related Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>suffer LUTS related BPH least 6 month ; IPSS &gt; 13 ; urinary peak flow rate 5.0 12.0 mL/s void volume least 150 mL ; residual urine volume &lt; = 200 mL .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>urinary tract</keyword>
</DOC>